[Aerosol administration of a replication defective recombinant adenovirus expressing normal human cDNA-CFTR in the respiratory tractus in patients with cystic fibrosis].
At present it is conceivable to think that gene therapy represents a way to treat or even prevent the respiratory manifestations of cystic fibrosis. Consistent to such a concept, there is sufficient evidence that Ad-CFTR, a recombinant replication-deficient adenovirus expressing the human cystic fibrosis transmembrane conductance regulator cDNA, can vectorize the expression of a functional CFTR (cystic fibrosis transmembrane conductance regulator) to the nasal and airway epithelia. The clinical protocol was designed to assess the safety of single escalating doses of a replication defective adenovirus expressing the cystic fibrosis transmembrane conductance regulator gene (Ad-CFTR) when administered to the tracheobronchial portion of the airways and whether biological efficacy of CFTR delivery could be demonstrated. Six cystic fibrosis patients received nasal instillation and subsequent aerosol (Optineb, Air Liquide, Paris, France) administration of Ad-CFTR the following day. Doses (pfu) applied to the nose were 10(5) (patients SG and PB), 10(7) (patients FP and EP) and 4 x 10(8) (patients DS and FG), while aerosolised doses were 10(7) (patients SG and PB), 10(8) (patients FP and EP) and 5.4 x 10(8) (patients DS and FG), respectively. No acute toxic effects, no increase in the titer of anti-adenovirus antibodies and no spreading or shedding of Ad-CFTR were detected. In one patient Ad-CFTR DNA was found in the urine and blood two days after aerosolisation. Ad-CFTR DNA was detected in nasal and bronchial brush samples, in BAL, in saliva and tonsils 21, 8, 14 and 4 days post virus administration, respectively. Ad-CFTR mRNA (RT-PCR on bronchial cells) and CFTR protein (immunochemistry on nasal and bronchial cells) were detected up to 14 days following Ad-CFTR administration. These results show that the nebulisation of Ad-CFTR is a possible approach for treating the respiratory manifestation of cystic fibrosis.
Bellon
G
G
Unité Pneumologie Pédiatrique-Mucoviscidose, Centre Hospitalier Lyon Sud, Pierre-Bénite.
Calmard
L
L
Thouvenot
D
D
Levrey
H
H
Jagneaux
V
V
Poitevin
F
F
Malcus
C
C
Accart
N
N
Séné
C
C
Layani
M P
MP
Aymard
M
M
Bienvenu
J
J
Courtney
M
M
Döring
G
G
Gilly
B
B
Gilly
R
R
Lamy
D
D
Morel
Y
Y
Paulin
C
C
Perraud
F
F
Rodillon
L
L
So
S
S
Touraine
F
F
Schatz
C
C
Pavirani
A
A
D000256:Adenoviridae / Q000235:genetics*; D000293:Adolescent; D000328:Adult; D000336:Aerosols; D000818:Animals; D003550:Cystic Fibrosis / Q000628:therapy*; D019005:Cystic Fibrosis Transmembrane Conductance Regulator / Q000008:administration & dosage* / Q000235:genetics*; D004274:DNA, Recombinant / Q000008:administration & dosage*; D003673:Defective Viruses / Q000235:genetics; D004361:Drug Tolerance; D018014:Gene Transfer Techniques; D015316:Genetic Therapy / Q000379:methods; D005822:Genetic Vectors / Q000235:genetics*; D006801:Humans; D011995:Recombination, Genetic; D012062:Relative Biological Effectiveness; D012137:Respiratory System / Q000821:virology
D000336:Aerosols; C505032:CFTR protein, human; D004274:DNA, Recombinant; D019005:Cystic Fibrosis Transmembrane Conductance Regulator